HopeStage
Back to all studies
CompletedNCT00186186

Divalproex extended release for bipolar depression and brain changes

About this titleRead the official source — NCT00186186

Researchers studied Depakote ER to find out how it affected depression symptoms in people with bipolarity during a depressive episode.

Medication studyAges 18–99United States
The study in practice

Understand this study

What did researchers investigate?

Researchers studied Depakote ER to find out how it affected depression symptoms in people with bipolarity during a depressive episode.

Who was this study for?

This study was for people with bipolarity. Listed age limits: 18 years to 99 years. Other eligibility criteria applied.

Listed locations
StanfordSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJanuary 2004
Recruitment status
Completed
Enrollment listed in the registry
28
Sponsor
Stanford University
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 18 Years to 99 Years
Official registry ID
NCT00186186
Official title
Show the full official title

Depakote ER in Bipolar Depression

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Stanford

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

Researchers studied Depakote ER to find out how it affected depression symptoms in people with bipolarity during a depressive episode.

Who is behind this study?

The study sponsor is Stanford University, a university.

Did this study involve medication?

Yes. The study involved medication, including Depakote ER.

Who was this study for?

This study was for people with bipolarity. Listed age limits: 18 years to 99 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies